DBV Technologies
DBV Technologies is a global clinical stage biopharmaceutical company dedicated to improving the lives of patients with food allergies and other immunological diseases. Founded by pediatricians, the company is focused on advancing epicutaneous immunotherapy using its innovative VIASKIN® patch technology. They are exploring treatments for food allergies, including peanut and milk allergies, and aim to develop a new class of immunotherapy to address unmet medical needs.
Industries
Nr. of Employees
medium (51-250)
DBV Technologies
Bâtiment IRO, 107 Av. de la République, 92320 Châtillon, France
Patents
Products
Investigational epicutaneous patch for peanut allergy
An investigational patch-based therapy designed to deliver minimal amounts of peanut antigen to the skin to induce immune modulation; part of a Phase 3 and long-term clinical development program.
Investigational epicutaneous patch for cow's milk allergy
An investigational patch therapy developed for cow's milk allergy that completed a Phase 1/2 study to evaluate safety and efficacy in pediatric and adolescent populations.
Investigational epicutaneous patch evaluated for cow's milk–induced EoE
Investigational patch studied in a clinical context for cow's milk–induced eosinophilic esophagitis; a Phase 2a study was completed (sponsored by an external hospital).
Investigational epicutaneous patch for peanut allergy
An investigational patch-based therapy designed to deliver minimal amounts of peanut antigen to the skin to induce immune modulation; part of a Phase 3 and long-term clinical development program.
Investigational epicutaneous patch for cow's milk allergy
An investigational patch therapy developed for cow's milk allergy that completed a Phase 1/2 study to evaluate safety and efficacy in pediatric and adolescent populations.
Investigational epicutaneous patch evaluated for cow's milk–induced EoE
Investigational patch studied in a clinical context for cow's milk–induced eosinophilic esophagitis; a Phase 2a study was completed (sponsored by an external hospital).
Services
Phone and online submission service for medical information inquiries from healthcare professionals and patients, with region-specific contact numbers and an online inquiry form.
Operational support to provide investigational therapy access to eligible patients outside of clinical trials through an expanded access program.
End-to-end clinical trial services including protocol development, trial execution across multiple phases, and long-term follow-up studies for investigational patch therapies.
Coordination of outsourced manufacturing and supply chain activities to support investigational product supply for clinical programs.
Phone and online submission service for medical information inquiries from healthcare professionals and patients, with region-specific contact numbers and an online inquiry form.
Operational support to provide investigational therapy access to eligible patients outside of clinical trials through an expanded access program.
End-to-end clinical trial services including protocol development, trial execution across multiple phases, and long-term follow-up studies for investigational patch therapies.
Coordination of outsourced manufacturing and supply chain activities to support investigational product supply for clinical programs.
Expertise Areas
- Epicutaneous immunotherapy development
- Clinical trial management (Phase I–III and long-term studies)
- Pediatric allergy therapeutics
- Medical affairs and medical information
Key Technologies
- Epicutaneous antigen delivery (EPIT)
- Patch-based transdermal delivery
- Clinical trial management platforms and processes
- Expanded access program operations